Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study
Abstract Background Real-world evidence on transition from standard-dose FVIII to Emicizumab prophylaxis in young children with hemophilia A remains limited, particularly in developing countries. Methods We performed a single-center, retrospective, self-controlled study in boys with severe hemophili...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2026-05-01
|
| Col·lecció: | Thrombosis Journal |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12959-026-00868-3 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|